K E Fattinger

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi [Interactions and adverse drug reactions: how to obtain information]
    K E Fattinger
    Abteilung für Klinische Pharmakologie und Toxikologie, Universitatsspital Zurich
    Praxis (Bern 1994) 88:713-8. 1999
  2. ncbi Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine
    K Fattinger
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Br J Clin Pharmacol 49:158-67. 2000
  3. ncbi No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients
    Karin Fattinger
    Dept of Medicine, University Hospital, Zurich, Switzerland
    Eur J Clin Pharmacol 57:863-7. 2002
  4. ncbi Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine
    K Fattinger
    Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, University of California, USA
    Eur J Clin Pharmacol 56:305-10. 2000
  5. ncbi The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions
    K Fattinger
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland
    Clin Pharmacol Ther 69:223-31. 2001
  6. ncbi [Antihypertensives--which adverse drug reactions are clinically relevant?]
    K Fattinger
    Abteilung Klinische Pharmakologie und Toxikologie, Departement Innere Medizin, Universitatsspital Zurich
    Praxis (Bern 1994) 93:871-6. 2004
  7. ncbi [Interactions of phytotherapeutic drugs, foods and drinks with medicines]
    K Fattinger
    Abteilung Klinische Pharmakologie und Toxikologie, Departement Innere Medizin, Universtätsspital Zürich
    Ther Umsch 59:292-300. 2002
  8. ncbi Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver
    N Hagenbuch
    Department of Medicine, University Hospital, Zurich, Switzerland
    J Hepatol 34:881-7. 2001
  9. ncbi Sensitive stereospecific determination of acenocoumarol and phenprocoumon in plasma by high-performance liquid chromatography
    K M Rentsch
    Institute of Clinical Chemistry, University Hospital Zurich, Switzerland
    J Chromatogr B Biomed Sci Appl 742:131-42. 2000
  10. ncbi Safety of liver donation after fatal intoxication with the tricyclic antidepressant trimipramine
    K E Fattinger
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Transplantation 62:1259-62. 1996

Collaborators

Detail Information

Publications16

  1. ncbi [Interactions and adverse drug reactions: how to obtain information]
    K E Fattinger
    Abteilung für Klinische Pharmakologie und Toxikologie, Universitatsspital Zurich
    Praxis (Bern 1994) 88:713-8. 1999
    ..It is essential for drug safety monitoring that every physician communicates observation of ADR...
  2. ncbi Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine
    K Fattinger
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Br J Clin Pharmacol 49:158-67. 2000
    ..To explore drug exposure, frequency of adverse drug reactions (ADRs), types of ADRs, predisposing risk factors and ADR-related excess hospital stay in medical inpatients...
  3. ncbi No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients
    Karin Fattinger
    Dept of Medicine, University Hospital, Zurich, Switzerland
    Eur J Clin Pharmacol 57:863-7. 2002
    ..In many European countries, phenprocoumon and not warfarin is used as an anticoagulant. However, the effects of paracetamol on the anticoagulant effects of phenprocoumon have so far not been evaluated...
  4. ncbi Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine
    K Fattinger
    Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, University of California, USA
    Eur J Clin Pharmacol 56:305-10. 2000
    ..The aim of this study was to estimate and compare cocaine input into the systemic circulation after oral and nasal dosing, and to determine the relevance of local absorption through the nasal mucosa...
  5. ncbi The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions
    K Fattinger
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland
    Clin Pharmacol Ther 69:223-31. 2001
    ..In this study we investigated whether inhibition of the hepatocanalicular bile salt export pump (rodents, Bsep; humans, BSEP ABCB11) could account for bosentan-induced liver injury...
  6. ncbi [Antihypertensives--which adverse drug reactions are clinically relevant?]
    K Fattinger
    Abteilung Klinische Pharmakologie und Toxikologie, Departement Innere Medizin, Universitatsspital Zurich
    Praxis (Bern 1994) 93:871-6. 2004
    ..Only the local or international accumulation of comparable spontaneous reports allows the drug regulation agencies to recognise new and unexpected adverse drug reactions early and to initiate appropriate measures...
  7. ncbi [Interactions of phytotherapeutic drugs, foods and drinks with medicines]
    K Fattinger
    Abteilung Klinische Pharmakologie und Toxikologie, Departement Innere Medizin, Universtätsspital Zürich
    Ther Umsch 59:292-300. 2002
    ....
  8. ncbi Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver
    N Hagenbuch
    Department of Medicine, University Hospital, Zurich, Switzerland
    J Hepatol 34:881-7. 2001
    ..The hepatic clearance of drugs and cholephilic organic anions is stimulated by phenobarbital (PB). Our aim was to analyze the effects of PB on the expression of hepatocellular bile salt and organic anion transporters...
  9. ncbi Sensitive stereospecific determination of acenocoumarol and phenprocoumon in plasma by high-performance liquid chromatography
    K M Rentsch
    Institute of Clinical Chemistry, University Hospital Zurich, Switzerland
    J Chromatogr B Biomed Sci Appl 742:131-42. 2000
    ..V.) (50-1800 microg/l) for R- and S-acenocoumarol was <4.7% within-day and <7.8% between-day. For R- and S-phenprocoumon the respective values were <5.6% and <5.9%. The accuracy for all compounds was 96.5-110%...
  10. ncbi Safety of liver donation after fatal intoxication with the tricyclic antidepressant trimipramine
    K E Fattinger
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Transplantation 62:1259-62. 1996
    ..If higher serum trimipramine concentrations are present, harvesting should be delayed to avoid trimipramine toxicity in the recipient...
  11. ncbi Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
    Stephan R Vavricka
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, , Switzerland
    Hepatology 36:164-72. 2002
    ..Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination...
  12. ncbi Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacol Ther 73:20-30. 2003
    ....
  13. ncbi Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts
    François Girardin
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland
    Clin Pharmacol Ther 74:341-52. 2003
    ..Therefore we characterized the pharmacokinetics of intramuscular and oral diacetylmorphine in the high dose range usually required in narcotic addicts...
  14. ncbi BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, A 8091 Zurich, Switzerland
    Hepatology 39:779-91. 2004
    ..Although an impact of rare variants on BSEP and MDR3 function cannot be ruled out, our data do not support a strong role of BSEP and MDR3 genetic variations in the pathogenesis of PBC and PSC...
  15. ncbi Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacokinet 41:137-52. 2002
    ..To compare the pharmacokinetic and pharmacodynamic characteristics of angiotensin II receptor antagonists as a therapeutic class...
  16. ncbi Incidence of drug-induced liver injury in medical inpatients
    Yvonne Meier
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital Zurich, CH-8091, , Switzerland
    Eur J Clin Pharmacol 61:135-43. 2005
    ..Incidences of DILI were highest for antineoplastic agents and tuberculostatics. DILI is frequently missed and, therefore, DILI detection by diagnoses will result in misleadingly low incidence rates...